Literature DB >> 10025983

Treatment of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin: an update.

G Merlini, E Anesi, P Garini, V Perfetti, L Obici, E Ascari, M H Lechuga, G Capri, L Gianni.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025983

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Amyloidosis.

Authors:  M F Khan; R H Falk
Journal:  Postgrad Med J       Date:  2001-11       Impact factor: 2.401

2.  Antibody-mediated resolution of light chain-associated amyloid deposits.

Authors:  R Hrncic; J Wall; D A Wolfenbarger; C L Murphy; M Schell; D T Weiss; A Solomon
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation.

Authors:  M P Sebastião; G Merlini; M J Saraiva; A M Damas
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

4.  Current therapeutic strategies in cardiac amyloidosis.

Authors:  Shailja Parikh; James A de Lemos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

Review 5.  Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.

Authors:  Romano Danesi; Stefano Fogli; Alessandra Gennari; Pierfranco Conte; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Primary systemic amyloidosis.

Authors:  R L Comenzo
Journal:  Curr Treat Options Oncol       Date:  2000-04

Review 7.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

Review 8.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.